Department of Dermatology, University of Roma Tor Vergata, 00133 Rome, Italy.
Int J Mol Sci. 2023 Sep 26;24(19):14535. doi: 10.3390/ijms241914535.
Melanoma is one of the deadliest skin tumors, accounting for almost 90% of skin cancer mortality. Although immune therapy and targeted therapy have dramatically changed the prognosis of metastatic melanoma, many patients experience disease progression despite the currently available new treatments. Skin metastases from melanoma represent a relatively common event as first sign of advanced disease or a sign of recurrence. Skin metastases are usually asymptomatic, although in advanced stages, they can present with ulceration, bleeding, and superinfection; furthermore, they can cause symptoms related to compression on nearby tissues. Treatments vary from simple surgery resections to topical or intralesional local injections, or a combination of these techniques with the most recent systemic immune or target therapies. New research and studies should focus on the pathogenesis and molecular mechanisms of the cutaneous metastases of melanoma in order to shed light on the mechanisms underlying the different behavior and prognoses of different patients.
黑色素瘤是最致命的皮肤肿瘤之一,占皮肤癌死亡人数的近 90%。尽管免疫疗法和靶向治疗显著改变了转移性黑色素瘤的预后,但许多患者尽管有目前可用的新治疗方法,仍会出现疾病进展。黑色素瘤的皮肤转移是一种相对常见的事件,作为晚期疾病的首发表现或复发的迹象。皮肤转移通常无症状,但在晚期阶段,可能出现溃疡、出血和继发感染;此外,它们可能导致与附近组织受压相关的症状。治疗方法从简单的手术切除到局部或病灶内的局部注射,或这些技术与最近的全身免疫或靶向治疗相结合。新的研究和研究应侧重于黑色素瘤皮肤转移的发病机制和分子机制,以阐明不同患者不同行为和预后的机制。